<DOC>
	<DOCNO>NCT02392026</DOCNO>
	<brief_summary>Multicenter , open-label study evaluate safety tolerability Metronidazole Vaginal Gel females 12 &lt; 18 year treatment bacterial vaginosis .</brief_summary>
	<brief_title>Safety Tolerability Metronidazole Gel 1.3 %</brief_title>
	<detailed_description>A multicenter , open-label study evaluate safety tolerability Metronidazole Vaginal Gel 1.3 % administer single dose adolescent female ( age 12 &lt; 18 year ) treatment bacterial vaginosis .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Provide write assent parent/legal guardian inform consent authorization disclose protected health information . Postmenarcheal , adolescent female , 12 &lt; 18 year age time Screening/Baseline Visit ( Day 1 ) . In good general health Screening visit know medical condition , Investigator 's opinion , may interfere study participation . Has negative urine pregnancy test result prior study treatment initiation . Has clinical diagnosis bacterial vaginosis . Agree abstain sexual intravaginal intercourse study duration . Willing avoid alcohol ingestion 24 hour administration test article . Agree refrain use intravaginal product duration study ( e.g . lubricate condom , tampon , diaphragm , spermicide , feminine deodorant spray , douche ) . Intravaginal Uterine Device ( IUD ) use acceptable long place 30 day prior study enrollment . Willing able participate study , make require visit study center , comply study requirement include concomitant medication treatment restriction . Pregnant , lactating , plan become pregnant study period . Currently menstruate anticipate onset menses first 9 day study . Experience clinically important medical event 90 day Screening/Baseline Visit ( Day 1 ) . Evidence infectious cause vulvovaginal infection condition Investigator 's opinion would confound interpretation study result . Severe symptom dysuria and/or pruritus , burn irritation vulvovaginal area . Received systemic intravaginal antifungal , antibacterial antiparasitic drug within 14 day Screening/Baseline visit ( Day 1 ) . Antiviral therapy ( nonintravaginal ) acceptable . Has take disulfiram systemic corticosteroid ( oral inject ) within 14 day Screening/Baseline Visit ( Day 1 ) . Had sexual intravaginal intercourse within 24 hour Screening/Baseline ( Day 1 ) . Demonstrated previous hypersensitivity metronidazole , either orally topically administer , form parabens benzyl alcohol . Known primary secondary immunodeficiency condition/syndrome . Being treat plan treat study period cervical intraepithelial neoplasia ( CIN ) cervical carcinoma . Using anticoagulation therapy Coumadin ( warfarin ) . Previously treat test article protocol . Participate experimental drug/device trial within last 30 day Screening/Baseline Visit ( Day 1 ) . Is judged Investigator unsuitable reason .</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>